Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus +/- Bevacizumab in Advanced Pancreatic Neuroendocrine Tumors
NCT01229943Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2010
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of bevacizumab in Pancreatic neuroendocrine tumor (PanNET), sponsored by National Cancer Institute. Started Oct 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01229943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01229943.